749927-80-8

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2-fluoro-N,N-dimethylbenzamide is used as a key intermediate in the synthesis of various pharmaceuticals for its potential to contribute to the development of new drugs. Its unique structure allows for the creation of molecules with specific biological activities, making it valuable in drug discovery and development processes.
Used in Agrochemical Industry:
In the agrochemical sector, 4-Bromo-2-fluoro-N,N-dimethylbenzamide serves as an intermediate in the production of compounds designed to protect crops and enhance agricultural yields. Its role in synthesizing agrochemicals underscores its versatility and importance in this field.
Used in Chemical Research and Analysis:
4-Bromo-2-fluoro-N,N-dimethylbenzamide is utilized as a reagent in chemical research, facilitating various experimental procedures and reactions. Additionally, it functions as a reference standard, enabling the accurate comparison and calibration of experimental results in analytical chemistry.
Overall, 4-Bromo-2-fluoro-N,N-dimethylbenzamide's applications reflect its significance in organic chemistry and its contribution to the advancement of pharmaceuticals, agrochemicals, and chemical research methodologies.

InChI:InChI=1/C9H9BrFNO/c1-12(2)9(13)7-4-3-6(10)5-8(7)11/h3-5H,1-2H3

Upstream product

• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 124-40-3 dimethyl amine 
• 151982-51-3 4-bromo-2-fluorobenzoyl chloride 
• 506-59-2 N,N-dimethylammonium chloride 

Downstream Products

• 874289-13-1 4-(N,N-dimethylcarbamoyl)-3-fluorophenylboronic acid 
• 1264616-33-2 2-fluoro-N,N-dimethyl-4-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide 
• 1008115-78-3 (5S)-2-[4-(dimethylaminocarbonyl)-3-fluorophenyl]-α,α-dimethyl-N-(1,3,4-thiadiazol-2-yl)-5H-[1]benzopyrano[2,3-b]pyridin-5-acetamide 

Relevant academic research and scientific papers

Development of a Practical Synthesis of Functionalized Azaxanthene-Derived Nonsteroidal Glucocorticoid Receptor Modulators

An efficient route to two functionalized 2-aryl-5H-chromeno[2,3-b]pyridines (azaxanthenes) is reported. The addition of lithiated 2,6-dichloropyridine to salicylaldehyde followed by cyclization was a key process improvement identified for the formation of the azaxanthene core. Further elaboration of 2-chloro-5H-chromeno[2,3-b]pyridin-5-ol at the 5 position was accomplished via Lewis acid-catalyzed coupling with commercially available ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane. A partial classical resolution coupled with a preparative chiral supercritical fluid chromatography (SFC) separation was used to isolate the desired enantiomer of the azaxanthene carboxylic acid that is a common intermediate for both compounds 1 and 2. Suzuki-Miyaura cross-coupling with appropriately substituted boronic acids, followed by condensation with 2-amino-1,3,4-thiadiazole, provided the target compounds with an overall yield of approximately 10%. The use of stable, amorphous materials to support clinical comparison of functionalized azaxanthenes 1 and 2 is also discussed.

HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS

Disclosed are novel nitrogen-containing, heterocyclic, c-Met inhibitor compounds, processes for their preparation and formulations thereof. The compounds are useful as therapeutical agents for the inhibition, regulation, and control of c-Met kinase signal pathway, and useful for treating in a subject a cell proliferative disorder or disorders mediated by c-Met.

A robust three-step telescoped synthesis of electron-deficient amide substituted arylboronic acids

A robust three-step telescoped process for the preparation of electron-deficient amide-substituted arylboronic acids from readily available bromobenzoic acids has been developed. An EDC-HOBT-promoted amide formation of a bromobenzoic acid was followed by subjection of the product stream to a palladium-mediated cross-coupling with B2(pin)2. The resultant mixture of the arylboronate ester and arylboronic acid was directly treated with NaIO4, followed by a heptane-MeTHF crystallization, to cleanly afford the corresponding arylboronic acid in good yield. This general procedure was used to synthesize electron-deficient amide-substituted arylboronic acids with a diverse array of electron-withdrawing substituents.

Imidazole pyrimidine amides as potent, orally bioavailable cyclin-dependent kinase inhibitors

The development of a novel series of imidazole pyrimidine amides as cyclin-dependent kinase (CDK) inhibitors is described. The series was found to have much improved CDK2 inhibition and potent in vitro anti-proliferative effects against cancer cell lines. Control of overall lipophilicity was important to achieve good in vitro potency along with acceptable physiochemical properties and margins against inhibition of both CYP isoforms and the hERG potassium ion channel. A compound with an attractive overall balance of properties was profiled in vivo and possessed suitable physiochemical and pharmacokinetic profiles for oral dosing.

4- (4- (IMIDAZOL-4-YL) PYRIMIDIN-2-YLAMINO) BENZAMIDES AS CDK INHIBITORS

Compounds of the formula: (I): wherein variable groups are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The invention relates to compounds of the formula (I) and to pharmaceutically acceptable salts, solvates, prodrugs and metabolites thereof, wherein W, Z, R1and R2, are as defined herein. The invention also relates to methods of treating Hepatitis C virus in mammals by administering the compounds of formula (I), and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula (I). The invention also relates to methods of preparing the compounds of formula (I).